RE:RE:RE:RE:RE:RE:RE:The recent Option Grant.With the greatest of respect, KBC, let me respond.
Now here is somebody (me) posting a contrary argument and your response is: "I can't be bothered arguing....". I have been presenting information and making argument for over ten years. I'm still doing it. If I choose to summarize all of that because I don't want to write it out for the 500th time then I think I've earned the right to do so.
I'll make what I think is an easy prediction. If there is a XB3-001 deal, you will be highly critical of it.
There is no reason to have confidence in the current management's ability to negotiate good deals. They sold four LSDs to Chiesi for $3 million, or $750,000 each. They retain the LSD, Hunter syndrome, in the pipeline. Is it also worth only $750,000 and $34.5 million in milestones? Why bother keeping it in the pipeline?
I made the case for a high valuation of xB3-001 by discussing the $7 billion AZ/DS deal for Enhertu. You quoted some if it. I didn't need to argue it again. Do I expect $7 billion? No, but anything in the low tens of millions up front and mid hundreds of millions in milestones will be a disappointment and would likely create a low value exit point for most shareholders. There would be a huge selloff below a dollar.
Finally, it is good and proper for shareholders to have high value expectations for xB3 drugs that are intended for high value, unmet needs.
Hold the damn management's feet to the fire! Expect lots!
Selling xB3 drugs for nothing is no accomplishment. Any fast food wicket tender could do it!
jd